MTOR and cancer: In addition, recent evidence indicates that 6-MP inhibits the phosphatidylinositol 3 kinase (PI3K) / mammalian target of rapamycin (mTOR) signaling pathway [8], suggesting that these drugs might interfere with metabolic checkpoints and impact metabolic reprogramming in normal T cells and cancer [19].